OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

I don't understand why there's been a great fall, I thought the clinical update was very positive - to the extent if they'd risen to 6p I might be a Buyer - but clearly the Market as a whole thinks this (result?) is Negative - were they expecting a OTC pill?
- oh no, I get it -Happy Pills, that's what they should have been making - and we've yet to hear if their "new facility" has be finished.

My comment yesterday, was premature, eh? "..However, there is not much evidence others think the same..."

So, who were part of tabasco's 'crew?'

Did try and tell him that drug comps were a waste of time but of course he knew better, hey ho.

Anyone understand why the recent News has been treated as "bad"?
EDIT(10Feb2012)- A.Wood steps aside as FD; pity. +I bought some more last month as near cash-value approaches.
EDIT(15Feb2012)-Oh deary, Dir add a few to his 300,000shares (£9K)DYOR. Not exactly a big invt?
EDIT(17April2012) - Big rise on PhI/II PD results, but these were expected, weren't they? Back soon to 3p I guess.
EDIT,(6Jn2012)- 3p04 now just, below latest buys, to be expected with the Greeks rioting again, soon. I'm hopeful it will rise=double figures like 60p before we're Out.

Sp lowest ever, director buying, large shareholder increases stake over 15per cent. Prob get bought out at 10p

Another winner Tabby ... ffs u can't half pick em.

BTW ... who you posting as now ?

Er we go

more stakebuilding?

back to what i paid for mine !!!
what to do now is the question.....

Interim Management Statement


PIPELINE HIGHLIGHTS
LentiVector® platform
Ocular programmes (gene-based therapies targeting vision loss): partnered with Sanofi
· First RetinoStat® Phase I results (n=6) presented at 2012 ARVO Annual Meeting on Monday, 7 May 2012 indicate sustained, dose-related protein expression in the eye
· Early data show a clear dose response1, with the 10-fold escalation to dose level 2 (n=3) yielding a similar increase in average protein expression

ProSavin® (gene-based therapy for Parkinson's disease): development update
· Phase I/II study successfully met primary endpoints: ProSavin® is safe, well-tolerated and mediates long-term improvement of motor function, announced in April 2012
· Summary of data to be presented at the ASGCT 15th Annual Meeting on Thursday, 17 May 2012

5T4 tumour antigen platform
TroVax® (therapeutic cancer vaccine): publication in Lung Cancer
· Article entitled "Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma" published in Lung Cancer in April 2012 which underpins the upcoming sponsored Phase II study for TroVax® in mesothelioma

Their new plant has been given approval and the sp drifts down - presumably because they have nothing to put in it.
Anyone know the formula for Whatsits?
A profit . . . .

sp abt. = 2p37
EDIT:(8Jy2012)- Oh deary and I'm understanding the Begging-Bowl is out again, no need to polish it, it was cleaned by we saps only recently.
Rights Issue and Open Offer (DYOR), suggests the City isn't too keen. . . . Have bought about 1/3 my entitlement only - wait and see, eh?
EDIT(24Jy2012)-sp 2p24 (Open/Rights=2p5) - so already cheaper to buy in the Market...Oh deary!
EDIT (3Aug2012)- 2p17 today . . . Hurrumph!
EDIT (8Aug2012):- Interim results of Retina trial seem to be positive (+ more patients recruit); reads like good news. sp 2p23
EDIT (1May2013)-Novartis deal - not enormous, but earns OXB abt 10% of Mkt Cap p.a. - and has lifted sp off 1p5... to just over 2p
EDIT (18July2013)- Oh deary, down to 1p45 -does the Market really know something???

I must say the recent (10 June 2013 - DYOR) round of Director Buys was pathetic . . . about £2k a piece that says "Sell" IMHO.
(- Levels above £50k-each, say "Buy" - )
Yet we read they have new funding for a Research programme and so on - but I didn't read any Cash-value . . . so poor old OXB struggles to find enough money to feed the elec.Meter, so the AIR-con can be returned to "Cool" - which is what Shareholders appear to get each year.

Brr!

Chart says it all . . . . . . . . . . . . . . . . . n o t h i n g


Robstuff - later Post - (EDIT 10Sept2013)-can't see any reason, maybe a rogue trader fell off his keyboard . . . . for any serious price-rise we need to see a sea-change in fortunes - and IMHO that can only come from Sales to a big Pharma - not a sell-out hopefully at 9p but product deals that change this from a scurrying-around for sweeties business - - to one at the adult-table with boxes full of repeat-orders. I Hope.
This stock has been poorly presented and managed (as far as loyal shareholders are concerned), that they "probably" need an injection of new blood . . . . to wrestle this from oblivion . . . .
EDIT (13Sept2013)- I think the reason was Director sm-purchase, nothing to get excited about . . . but a Buy, is a buy...expect slippage.
EDIT (27Jan2014)- 3p5 Looks like Market is +ve on this now . . . maybe 2014 is THE year we've waited for . . . so very long...

Has something leaked? - up 27% today

anyone know why the rise - up 30%!!

You were right robstuff and now we know why - this is a big one and a major step in the right direction.

Up another 12% to-day - Its been a long patient (!) (prostate) wait but looking worthwhile even from a financial point of view.

Something stirring, next week indications are good, other boards have something under wraps too, dyor

My own prediction is that Oxb has something extraordinary and is going to zoom. But have thought that for 17 yrs

Could we about to see Oxb come good 2014.

Have been studying charts for a few months too, was previously skeptical but an expert showed me and applied to Oxb found in early stages o a rebirth, let's hope, it's got a long long way to recover

Another good reaction to a RNS and more to come next week following a presentation over the pond.

Here we go again